“Not on the fast track to academic success? Try the slow road - PhysOrg” plus 3 more |
- Not on the fast track to academic success? Try the slow road - PhysOrg
- Thermo Fisher to acquire Finnzymes - New Statesman
- Algenol Partners With Lee County as Commission Votes to Approve ... - YAHOO!
- Molecular Devices Returns to Life Sciences Marketplace - MSN Money
| Not on the fast track to academic success? Try the slow road - PhysOrg Posted: 03 Feb 2010 07:24 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. Not on the fast track to academic success? Try the slow roadFebruary 3, 2010How do scientists decide what to investigate? Often, they choose an area that is in high demand, hoping to get their work into the best journals as soon as possible. According to Uri Alon, of the Weizmann Institute of Science in Israel, this strategy can be demotivating if the goals are not met, especially to younger scientists. Instead, he advises researchers to follow a less direct approach, where setbacks are considered part of the process of discovery. Ronen Zaidel-Bar recommends the article on the f1000 Biology website. "In the face of the cruel reality of 'publish or perish', Uri Alon offers some clear guidelines to help students and mentors nurture self-motivated research", writes Zaidel-Bar. Alon's commentary, published in the journal Molecular Cell, gives practical advice for researchers at all stages of their career. He encourages scientists to take time before they commit to a problem, and ultimately choose what they find most interesting, rather than what is in demand. Zaidel-Bar, who is a postdoctoral researcher at the University of Wisconsin-Madison, agrees that "research motivated by our true interest is much more rewarding and resilient to the setbacks of scientific inquiry." More information: Ronen Zaidel-Bar, Faculty Member for F1000 Biology, is a senior postdoctoral researcher at the University of Wisconsin - Madison http://f1000biology.com/about/biography/3198434723902519 Provided by Faculty of 1000: Biology and Medicine
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Thermo Fisher to acquire Finnzymes - New Statesman Posted: 03 Feb 2010 02:09 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. The acquisition expands Thermo Fisher's portfolio of reagents and other consumables for the molecular biology research and diagnostics markets through the addition of its proprietary DNA polymerases, Phire and Phusion, and high-speed miniaturized thermal cyclers, plastic tubes and plates. These products complement Thermo Scientific's recently launched Solaris qPCR gene expression assays. The company said that combining its gene-specific MGB-based probes with the advanced enzyme performance from Finnzymes, will further enhance qPCR assay technology. Finnzymes will be integrated primarily into Thermo Fisher's Analytical Technologies segment, with some equipment and consumables product lines being added to the Laboratory Products and Services segment. The transaction is expected to close during the first quarter of 2010. Marc Casper, president and chief executive officer of Thermo Fisher Scientific, said: "The addition of Finnzymes' innovative enzyme portfolio and unique PCR instrument platform strengthens our broad range of life science reagents and consumables, as well as our specialty diagnostics product offering. This combination brings together key complementary technologies for molecular biology and diagnostics, allowing us to create significant value for our customers." Finnzymes provides solutions for high-performance polymerase chain reaction (PCR), reverse transcription-PCR (RT-PCR) and real-time quantitative PCR (qPCR). Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Algenol Partners With Lee County as Commission Votes to Approve ... - YAHOO! Posted: 03 Feb 2010 07:31 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. Lee County Facility to Bring Economic Diversity and Jobs to Florida BONITA SPRINGS, Fla., Feb. 3 /PRNewswire-USNewswire/ -- Algenol Biofuels Inc. today announced that the company has reached an agreement with the Lee County Board of Commissioners to support the opening of a new 43,000 square foot facility in Lee County, bringing economic diversity and jobs to the area launching in the first quarter of 2010. The $10 million grant is an investment that can bring numerous opportunities in the burgeoning biofuels industry to the region as Algenol continues the development and expansion of its unique Direct to Ethanol ® process to produce low-cost ethanol and green chemicals from algae, sunlight, saltwater, and carbon dioxide. "We are very pleased the Lee County Commission is making it possible for Algenol, a Bonita Springs-based company, to significantly expand its local presence and continue our work to lessen our dependence on foreign oil, develop a solution for carbon pollution related issues, while bringing jobs to the area. We are very proud to be partners with Lee County and we are thankful for the extraordinary efforts of Commission Chairperson Tammy Hall, Commissioner Ray Judah, and Commissioner Bob Janes," said Paul Woods, CEO and founder of Algenol Biofuels. Commissioner Hall said, "We have an opportunity with this partnership to diversify the economic environment in Lee County. It will create expansion of research and development at Florida Gulf Coast University as well as create an opportunity for catalyst companies engaging in research to join Algenol, which translates to higher wage jobs and career opportunities not currently found in Lee County." "Our partnership with Algenol is an investment in American ingenuity and innovation," said Commissioner Ray Judah. "We are excited to welcome a Bio Technology company of this caliber to our community," says Jim Moore, Director of the Fort Myers Regional Partnership, Lee County's Economic Development Office. "This is a sector we hope to continue to expand in the near future." The facility will house Algenol's advanced biology and engineering laboratories, operations and 40 acres of land that will hold the company's unique photobioreactors – the containers that generate the ethanol from algae, saltwater and carbon dioxide. In addition to producing low-cost ethanol, Algenol is beginning to work on related projects, such as using its ethanol and other green chemicals as a replacement for petroleum in plastic building blocks. This new facet of the business will also be housed at the Lee County facility. The steps the Lee County Commission has taken to bring Algenol to the area echo the key findings in a recent report issued by Florida Gulf Coast University's Lutgert College of Business through their Regional Economic Research Institute. The report centered on the best ways to overcome the impact of the economic crisis and resulting recession is to create jobs and diversify regional economies by providing economic assistance that support business recruitment, retention and expansion of businesses and entrepreneurial assistance to high tech and green tech companies in the region. The opening of the Algenol facility in Lee County addresses all three proposed areas that will reinvigorate the local economy. In addition to bringing jobs to the area, Algenol plans to immediately form partnerships with local universities, including Florida Gulf Coast University and the University of Florida, to assist in establishing programs for students interested in pursuing careers in the green chemistry and biofuels industries, as well as to pursue the study of and solutions for red tides in Florida waters. Algenol Biofuels, Inc. is a privately owned company founded in 2006. It recently made a series of announcements including the award of a $25 million grant from the Department of Energy as part of the American Recovery and Reinvestment Act, to build a facility in Freeport, Tex. in concert with its partner on the project, The Dow Chemical Company (NYSE: DOW). Algenol also announced a partnership with The Linde Group to develop CO(2) capture and management technologies to increase biofuel production from algae. Algenol today possesses the most advanced third generation biofuel technology in the United States. Algenol makes low cost ethanol directly from CO(2) and seawater using hybrid algae in sealed, clear plastic photobioreactors through its unique, patented Direct to Ethanol ® technology — all powered by the sun. Algenol's research and development efforts have culminated in a process that produces over 6,000 gallons of ethanol per acre per year, compared to corn at 400. This process achieves an energy balance of more than 5 to 1 and a life cycle carbon footprint that is merely 20 percent of petroleum (an 80 percent reduction from petroleum). For more information about Algenol Biofuels, please visit www.algenolbiofuels.com. SOURCE Algenol Biofuels, Inc.
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Molecular Devices Returns to Life Sciences Marketplace - MSN Money Posted: 03 Feb 2010 05:22 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. New Brand Launched by Molecular Devices, Inc. SUNNYVALE, Calif., Feb. 3 /PRNewswire/ -- Today, Molecular Devices, Inc.--now part of Danaher Corporation--re-launched the Molecular Devices brand into the life sciences marketplace. The renewed corporate brand is focused primarily on meeting customer needs and exceeding customer expectations, and includes an evolved visual identity system. A new logo illustrates the company's commitment to provide high-performance analytical technologies that support the scientific success of its customers: the company's instrument--the customer's biology. First introduced more than 25 years ago, the Molecular Devices brand has earned increasing value in life sciences markets, becoming a well-recognized and sought-after brand for analytical instrumentation. Now, as part of the Danaher Medical Technologies segment, Molecular Devices, Inc. is focused on renewing its brand, seeking to retain and rebuild many of its historical attributes while adding new ones that translate into direct value for customers. "Our employees are excited about a new Molecular Devices brand that is focused primarily on serving our customers to the best of our abilities," said Tom Olenic, Vice President and General Manager for Molecular Devices, Inc. "The acquisition has given us a chance to take a close look at the way we do business and, in doing so, to identify the way we could be doing business--it's a tremendous opportunity, and we are definitely taking full advantage of it." Going forward, Molecular Devices will have a singular focus--its customers. Whether a long-time user, recent adopter, or prospective customer, their needs will fuel the company's actions. By hiring and retaining creative, best-in-class people, Molecular Devices will continue to design, manufacture, and commercialize analytical instruments, software, and assays to support the scientific success of its customers, regardless of objective: publication, compound hits, lead compounds, new molecular entity, bioassay, biotest, etc. The company will also provide dedicated, follow-on support to ensure that customer needs and expectations continue to be met over time. According to Tom Driscoll, Vice President of Global Marketing for Molecular Devices, Inc., "Understanding each customer's unique laboratory workflow continues to be a top priority, and we will direct product development efforts toward solving customer issues and optimizing customer workflows. Our goal now, as a new Molecular Devices brand, is to deliver highly relevant analytical products and services to detect biology, decode data, and drive successful life science discovery in both applied and basic research environments." Today, the Molecular Devices brand includes specialized products, services, and expertise for microplate, microarray, and label-free analysis; high-content and research imaging; automated and conventional electrophysiology; cellular screening; laser capture microdissection; and contaminant detection. Its products offer a full range of detection technologies and can meet all throughput needs to help drive success in basic research--from molecular to cellular to systems biology--as well as applied research--from discovery to development to production of new drugs, vaccines, and tests. Some of the business' top product brands, which will also undergo renewal this year, include: SpectraMax®, ImageXpress®, Axon(TM), IonWorks®, Threshold®, CellKey(TM), FLIPR®, and Arcturus®. About Molecular Devices, Inc. Founded in 1983, Molecular Devices Corporation introduced its first microplate reader in 1987 and has continually broadened its product and service portfolio through a combination of internal research and development and strategic acquisitions, including Universal Imaging Corporation (2002), Axon Instruments (2004), and Blueshift Biotechnologies, Inc. (2006). In 2007, Molecular Devices Corporation was acquired by MDS Inc. and integrated into its MDS Analytical Technologies division. And, in 2010, the business was acquired by Danaher Corporation and now operates independently as part of its Medical Technologies segment. Molecular Devices, Inc. designs, develops, and commercializes high-performance analytical instruments, software, and reagents to help drive success in basic life sciences research, drug discovery, biologics development and production, and bioassay and biotest development. The business is in the process of returning a renewed, independent Molecular Devices brand to the life sciences marketplace, with a focus on delivering unique value to customers. More information can be found at www.MolecularDevices.com. Molecular Devices®, the Molecular Devices logo, SpectraMax®, ImageXpress®, Axon(TM), IonWorks®, Threshold®, CellKey(TM), FLIPR®, Arcturus®, and all other trademarks are the property of Molecular Devices, Inc. SOURCE Molecular Devices, Inc. Copyright 2010 PR Newswire Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| You are subscribed to email updates from Biology - Bing News To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
0 comments:
Post a Comment